Clinical Research Directory

Antibody Responses to Pneumococcal Vaccines Among HIV-infected Adults.

Sponsor: ANRS, Emerging Infectious Diseases

Summary

Streptococcus pneumoniae is the major cause of bacterial infection in HIV-infected patients. The current pneumococcal vaccine is poorly efficacious in patients with a CD4 cell count lower than 500/mm3. This study will test the efficacy and safety of a new pneumococcal vaccine strategy in patients with a CD4 cell count between 200 and 500/mm3.

Official title: Immunological Efficacy of a Prime-boost Strategy Combining a 7-valent Pneumococcal Conjugate Vaccine (PCV) Followed by a 23-valent Pneumococcal Polysaccharide Vaccine (PPV) Versus PPV Alone in HIV-infected Adults. ANRS 114 PNEUMOVAC.

Key Details

Conditions

Interventions

Locations (1)